雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Analyses of IDH1 Mutation and MGMT Promoter Methylation Status for 5 Cases of Long-term Survivors with Glioblastoma Yuuta KAMOSHIMA 1 , Hiroaki MOTEGI 1 , Shunsuke TERASAKA 1 , Hiroyuki KOBAYASHI 1 , Shigeru YAMAGUCHI 2 , Junichi MURATA 2 , Shinya TANAKA 3 , Kiyohiro HOUKIN 1 1Department of Neurosurgery,Graduate School of Medicine,Hokkaido University 2Department of Neurosurgery,Sapporo Azabu Neurosurgical Hospital 3Laboratory of Cancer Research,Department of Pathology,Graduate School of Medicine,Hokkaido University Keyword: glioblastoma multiforme , long-term survival , IDH , MGMT pp.129-135
Published Date 2012/2/10
DOI https://doi.org/10.11477/mf.1436101645
  • Abstract
  • Look Inside
  • Reference

 Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with an extremely poor prognosis in spite of multimodal treatment approaches.

 The median survival time of patients with GBM is 15 months, and only 3-5% of patients survive longer than 36 months. Those patients who survive over 36 months after the initial diagnosis are defined as long-term survivors.

 In this study,we retrospectively performed clinical and molecular analyses of five long-term survivors of GBM (>36 months) and twenty four GBM patients with poor survival time as control group (<36 months) to identify any prognostic factors that potentially contribute to survival. The O6-methylguanine-DNA methyltransferase (MGMT) gene methylation status was evaluated by performing methylation specific polymerase chain reaction assays. The mutation of isocitrate dehydrogenase 1 and 2 were evaluated by the direct sequencing method. All five cases were primary GBMs and the coexistence of the oligodendroglioma component was checked for each case as GBM with oligodendroglioma component. All five cases showed MGMT promoter methylation (5/5). IDH1 mutation was detected in two of the long-term survivors with oligodendroglioma component (2/5) while no IDH1 mutation was detected in the control group. All patients were treated by gross total removal followed by radiotherapy and various chemotherapies including temozolomide. MGMT promoter methylation and IDH1 mutation might be favorable factors for long-term survival in GBM patients.


Copyright © 2012, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1251 印刷版ISSN 0301-2603 医学書院

関連文献

もっと見る

文献を共有